Supernus Pharmaceuticals (SUPN): FDA-Approved Neurological Medications & Portfolio Insights
Supernus Pharmaceuticals’ Q4 results reveal a critical inflection point for neurological drug development, with eight FDA-approved medications now shaping treatment paradigms for epilepsy, ADHD, and Parkinson’s disease. This week’s financial ... Read More